IMVT (Immunovant, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by IMVT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-28 | Atul Pande | Director | MIXED | — | — |
| 2026-08-21 | Melanie Gloria | Chief Operating Officer | Sell | — | — |
| 2026-07-24 | Jay S Stout | Chief Technology Officer | Sell | — | — |
| 2026-07-24 | Tiago Girao | Chief Financial Officer | Sell | — | — |
| 2026-07-24 | Atul Pande | Director | MIXED | — | — |
| 2026-07-10 | Melanie Gloria | Chief Operating Officer | Sell | — | — |
| 2026-07-10 | Christopher Van Tuyl | Chief Legal Officer | Sell | — | — |
| 2026-07-10 | Jay S Stout | Chief Technology Officer | Sell | — | — |
| 2026-07-06 | Eric Venker | Chief Executive Officer | MIXED | — | — |
| 2026-06-26 | Melanie Gloria | Chief Operating Officer | Sell | — | — |
| 2026-06-26 | Christopher Van Tuyl | Chief Legal Officer | MIXED | — | — |
| 2026-06-26 | Atul Pande | Director | MIXED | — | — |
| 2026-06-26 | Jay S Stout | Chief Technology Officer | Sell | — | — |
| 2026-06-26 | Tiago Girao | Chief Financial Officer | MIXED | — | — |
| 2026-06-22 | Christopher Van Tuyl | Chief Legal Officer | Sell | — | — |
| 2026-06-16 | Atul Pande | Director | MIXED | — | — |
| 2026-05-29 | Andrew J. Fromkin | Director | MIXED | — | — |
| 2026-05-22 | Melanie Gloria | Chief Operating Officer | Sell | — | — |
| 2026-05-20 | Atul Pande | Director | MIXED | — | — |
| 2026-05-01 | Robert Graham Susman | Director | Sell | — | — |
| 2026-04-24 | Jay S Stout | Chief Technology Officer | Sell | — | — |
| 2026-04-24 | Tiago Girao | Chief Financial Officer | Sell | — | — |
| 2026-04-10 | Melanie Gloria | Chief Operating Officer | Sell | — | — |
| 2026-04-10 | Jay S Stout | Chief Technology Officer | Sell | — | — |
| 2026-04-10 | Christopher Van Tuyl | Chief Legal Officer | Sell | — | — |
| 2026-04-09 | Jake Bauer | Director | A | — | — |
| 2026-04-09 | Eric Venker | Chief Executive Officer | A | — | — |
| 2026-04-09 | Andrew J. Fromkin | Director | A | — | — |
| 2026-04-09 | Robert Graham Susman | Director | A | — | — |
| 2026-04-09 | Jay S Stout | Chief Technology Officer | A | — | — |
| 2026-04-09 | Atul Pande | Director | A | — | — |
| 2026-04-09 | Christopher Van Tuyl | Chief Legal Officer | A | — | — |
| 2026-04-09 | Douglas J. Hughes | Director | A | — | — |
| 2026-04-09 | Frank Torti | Director | A | — | — |
| 2026-04-09 | Tiago Girao | Chief Financial Officer | A | — | — |
| 2026-04-09 | Melanie Gloria | Chief Operating Officer | A | — | — |
| 2026-04-03 | Eric Venker | Chief Executive Officer | MIXED | — | — |
| 2026-03-20 | Christopher Van Tuyl | Chief Legal Officer | Sell | — | — |
| 2026-02-27 | Melanie Gloria | Chief Operating Officer | Sell | — | — |
| 2026-01-23 | Jay S Stout | Chief Technology Officer | Sell | — | — |
| 2026-01-09 | Jay S Stout | Chief Technology Officer | Sell | — | — |
| 2025-12-19 | Christopher Van Tuyl | Chief Legal Officer | Sell | — | — |
| 2025-12-12 | Roivant Sciences Ltd. | Director | Buy | — | — |
| 2025-12-03 | Andrew J. Fromkin | Director | Sell | — | — |
| 2025-12-03 | Douglas J. Hughes | Director | Sell | — | — |
| 2025-11-21 | Melanie Gloria | Chief Operating Officer | Sell | — | — |
| 2025-10-24 | Michael Geffner | Chief Medical Officer | Sell | — | — |
| 2025-10-24 | Jay S Stout | Chief Technology Officer | Sell | — | — |
| 2025-10-10 | Michael Geffner | Chief Medical Officer | Sell | — | — |
| 2025-10-10 | Jay S Stout | Chief Technology Officer | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 113,317,007 | — |
| — | Chief Executive Officer | 1,178,191 | — |
| — | Director | 1,009,228 | — |
| — | Chief Development Officer | 441,079 | — |
| — | Chief Financial Officer | 396,774 | — |
| — | Chief Medical Officer | 357,353 | — |
| — | Chief Legal Officer | 319,228 | — |
| — | Chief Executive Officer | 257,372 | — |
| — | Chief Financial Officer | 240,798 | — |
| — | Chief Operating Officer | 219,301 | — |
| — | Chief Medical Officer | 217,958 | — |
| — | Chief Technology Officer | 205,341 | — |
| — | Chief Legal Officer | 179,391 | — |
| — | Director | 138,231 | — |
| — | Director | 137,251 | — |
| — | Director | 134,653 | — |
| — | Director | 131,400 | — |
| — | Chief Medical Officer | 117,600 | — |
| — | Chief Scientific Officer | 97,600 | — |
| — | Chief Financial Officer | 46,200 | — |
| — | Director | 38,896 | — |
| — | Director | 36,394 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the IMVT quote page; the site-wide leaderboard is on the insider transactions hub.